Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HN2301 for Refractory Graves' Disease
NCT07333677Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HN-2301 in Graves' disease, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Incidence and severity of Adverse Events at 3 months and Remission of Graves' disease at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
HN-2301
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07333677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333677.